Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study

Vittorio Gebbia, Antonio Russo, Moretti, Giovanardi, Antonella Ferro, Cagossi, Federico Piacentini, Beano, Alba Brandes, Conte, Balduzzi, Vicini, Rimanti, Ornella Garrone, Saverio Danese, Michele Aieta, Giancarlo Bisagni, Roberto D'Amico, Lombardo, Alessio SchironeRoberta Maltoni, Claudio Zamagni, Francesco Giotta, Bisagni, Frassoldati, Michela Donadio, Cavanna, Molino, Paolo Pronzato, Laura Amaducci, Antonino Musolino, Valentina Guarneri

Risultato della ricerca: Articlepeer review

56 Citazioni (Scopus)


Background: Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy. Patients and methods: HER2-positive breast cancer patients with node-positive or, if node negative, with at least one risk factor (pT>2 cm, G3, lympho-vascular invasion, Ki-67 > 20%, age 35 years, or hormone receptor negativity) were randomly assigned to receive sequential anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or plus 9 weeks trastuzumab (arm B, short). This study was designed as a non-inferiority trial with disease-free survival (DFS) as primary end point. A DFS hazard ratio (HR) <1.29 was chosen as the non-inferiority margin. Analyses according to the frequentist and Bayesian approach were planned. Secondary end points included 2-year failure rate and cardiac safety. Results: A total of 1254 patients from 82 centers were randomized (arm A, long: n ¼ 627; arm B, short: n ¼ 626). Five-year DFS is 88% in the long and 85% in the short arm. The HR is 1.13 (90% CI 0.89-1.42), with the upper limit of the CI crossing the non-inferiority margin. According to the Bayesian analysis, the probability that the short arm is non-inferior to the long one is 80%. The 5-year overall survival (OS) is 95.2% in the long and 95.0% in the short arm (HR 1.07, 90% CI 0.74-1.56). Cardiac events are significantly lower in the short arm (risk-ratio 0.33, 95% CI 0.22-0.50, P < 0.0001). Conclusions: This study failed to show the non-inferiority of a shorter trastuzumab administration. One-year trastuzumab remains the standard. However, a 9-week administration decreases the risk of severe cardiac toxicity and can be an option for patients with cardiac events during treatment and for those with a low risk of relapse. Trial Registration: EUDRACT number: 2007-004326-25; NCI number: NCT00629278.
Lingua originaleEnglish
pagine (da-a)2328-2333
Numero di pagine6
RivistaAnnals of Oncology
Stato di pubblicazionePublished - 2018

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2720???
  • ???subjectarea.asjc.2700.2730???


Entra nei temi di ricerca di 'Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study'. Insieme formano una fingerprint unica.

Cita questo